Eutropics to Present Data on Personalized Diagnostic for Leukemia Patient Management at ASH 2013
Cambridge, Mass. Eutropics Pharmaceuticals will present data from two recent clinical investigations at the 55th Annual American Society for Hematology Meeting to be held in New Orleans, LA December 7-11, 2013. These studies demonstrate the medical utility of Eutropics’ proprietary biomarker platform, PraediCare-Dx (aka BH3 profiling), in predicting patient response to cancer treatment.
The first study entitled “Mcl-1 Dependence Predicts Response to Vorinostat and Gemtuzumab Ozogamicin in Acute Myeloid Leukemia” was conducted in collaboration with researchers from the Fred Hutchinson Cancer Research Center in Seattle, WA and Stanford University. It will be presented as a poster on Saturday, December 7, 2013 from 5.30pm-7.30pm and highlights that Acute Myeloid Leukemia patients displaying a specific molecular profile showed improved outcomes to epigenetic modifying drug in combination with antibody-drug conjugate therapy. Dr. Roland Walter, an assistant member of the Clinical Research Division at Fred Hutch, was the principal investigator of the study.
A second collaborative study, “BH3 Profiling As Predictor Of 5-Azacytidine and Decitabine Clinical Responses” will be delivered in an oral presentation on Monday, December 10, 2013 at 4.45pm by Dr. Raoul Tibes of the Mayo-Clinic (Scottsdale, AZ). Here, patients with myeloid malignancies displayed specific profiles statistically associated with improved outcomes to DNA methyltransferase inhibitors.
“We are pleased to continue development of PraediCare-Dx and validate its clinical utility as a biomarker to aid physicians in personalized medicine strategies,” said Michael Cardone, CEO of Eutropics. “Collaborations with institutions such as Mayo Clinic and Fred Hutch drive advancement of these strategies that ultimately will positively affect patient treatment decisions and outcomes.”
Eutropics’ technology platform, PraediCare-Dx, delivers medically useful in vitro diagnostic assays. The tests may improve patient outcome by directing the best treatment options and provide a biomarker for guided cancer drug development. Based on clinical evidence, PraediCare-Dx delivers unique understanding into a cancer cell’s ability to respond to chemotherapies that induce programmed cell death (apoptosis), enabling the physician to choose the treatment option most likely to benefit the individual patient. Tests based on the PraediCare-Dx technology are being investigated for use in treating acute myeloid leukemia, chronic lymphocytic leukemia, and multiple myeloma.
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.